Metastatic gastric cancer

12 trials 7 recruiting MedDRA PT
12 Registered trials
7 Recruiting
10 Unique sponsors
12 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 9
L Oncology (ATC L) 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Platinum compound 2 substances
Checkpoint inhibitor (PD-1) 1 substance
Monoclonal antibody (chimeric) 1 substance
Antimetabolite 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Antibody-drug conjugate (ADC) 1 substance
Monoclonal antibody (immune) 1 substance
Phase III: 4 Phase II: 1 Phase I/II: 1 Phase I: 4 Phase I (First in Human): 2

Filter these 12 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 12 trials

Phase III

4 trials
  • Astellas Pharma Global Development Inc. Commercial
    PEMBROLIZUMAB; ZOLBETUXIMAB
    2024-519773-19-00 11 countries 2025 n=201 Orphan
    Ended
  • Daiichi Sankyo Inc. Commercial
    CISPLATIN; FLUOROURACIL; OXALIPLATIN; PEMBROLIZUMAB; TRASTUZUMAB; TRASTUZUMAB DERUXTECAN
    2024-513122-27-00 12 countries 2025 n=214
    Recruiting
  • Shanghai Henlius Biotech Inc. Commercial
    HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2
    2024-516633-12-00 7 countries 2025 n=106
    Recruiting
  • Karolinska University Hospital Academic
    IMP not specified
    2024-514879-17-00 4 countries 2025 n=96
    Recruiting

Phase II

1 trial

Phase I/II

1 trial
  • Merck Healthcare KGaA Commercial
    PRECEMTABART TOCENTECAN
    2024-517817-34-00 5 countries 2025 n=45
    Ended

Phase I

4 trials
  • BeOne Medicines AG Commercial
    IMP not specified
    2024-514704-13-00 1 country n=30
    Ended
  • Incyte Corp. Academic
    IMP not specified
    2023-504400-29-00 1 country 2022 n=9
    Ended
  • Vall D Hebron Institute Of Oncology Academic
    IMP not specified
    2024-516660-28-00 1 country n=15
    Not authorised
  • Vall D Hebron Institute Of Oncology Academic
    IMP not specified
    2024-516660-28-01 1 country 2026 n=15
    Recruiting

Phase I (First in Human)

2 trials
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
  • Ona Therapeutics S.L. Academic
    ONA-255
    2025-522233-62-00 1 country 2025 n=117
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Daiichi Sankyo Inc. Commercial 2 Phase III, Phase I (First in Human) 2
Vall D Hebron Institute Of Oncology Academic 2 Phase I 1
BeOne Medicines AG Commercial 1 Phase I 0
Astellas Pharma Global Development Inc. Commercial 1 Phase III 0
Shanghai Henlius Biotech Inc. Commercial 1 Phase III 1
Merck Healthcare KGaA Commercial 1 Phase I/II 0
Incyte Corp. Academic 1 Phase I 0
Gercor Academic 1 Phase II 1
Karolinska University Hospital Academic 1 Phase III 1
Ona Therapeutics S.L. Academic 1 Phase I (First in Human) 1
New trials by year
2022
1
2023
1
2025
7
2026
1
← All indication landscapes